Clinical Trial Update: Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks

View source ↗

Summary

A post-authorization safety study evaluating the Euforvac-Hib vaccine for active primary immunization in infants starting at 6 weeks to monitor safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• Euforvac-Hib Vaccine

Snippet

Sponsor: LG Life Sciences | Conditions: Diphtheria, Tetanus | Status: UNKNOWN